Moderna (NASDAQ:MRNA) Stock Sale Revealed by Rep. Maria Elvira Salazar

Posted by James Conley on Oct 9th, 2026

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on October 7th, the Representative disclosed that they had sold between $1,001 and $15,000 in Moderna stock on September 24th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Citigroup (NYSE:C) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/24/2026.
Sold $1,001 – $15,000 in shares of GE Aerospace (NYSE:GE) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 9/24/2026.
Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 9/24/2026.
Sold $1,001 – $15,000 in shares of RH (NYSE:RH) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 9/24/2026.

Moderna Stock Performance

NASDAQ:MRNA opened at $197.00 on Friday. The firm has a 50-day moving average of $136.67 and a two-hundred day moving average of $83.94. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The stock has a market cap of $78.65 billion, a P/E ratio of -24.66 and a beta of 1.09. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $212.22.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. The firm had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.Moderna’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($2.13) earnings per share. On average, research analysts expect that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

More Moderna News

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Moderna is scheduled to rejoin the Nasdaq-100 before the October 9 open, replacing Warner Bros. Discovery. The inclusion follows a significant increase in Moderna’s market capitalization and could create additional buying demand from index-tracking funds. Moderna Was Removed From the Nasdaq-100 and Is Going Back In
Positive Sentiment: Moderna and Merck expanded a multi-year collaboration with Tempus to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized cancer vaccine being studied with Keytruda. The agreement reinforces Moderna’s strategy to build a commercial oncology franchise beyond COVID-19 vaccines. Tempus Announces Multi-Year Collaboration with Moderna and Merck
Positive Sentiment: Recent coverage highlights Moderna’s efforts to apply lessons from its COVID-era manufacturing network to produce cancer therapies at scale. Successful execution could improve investor confidence in the company’s ability to commercialize multiple products.
Neutral Sentiment: An experimental AI-enabled approach that could reduce or eliminate cold-storage requirements for mRNA vaccines may lower distribution costs across the industry, but the technology is early-stage and does not represent an immediate Moderna revenue catalyst. Experimental Approach Uses AI to Eliminate Cold Storage for mRNA Vaccines
Negative Sentiment: Morgan Stanley maintained an Equal Weight rating and raised its price target only to $95, well below the roughly $197 trading level cited in the reports. The valuation gap signals substantial downside risk after Moderna’s powerful rally. Moderna Gets a Hold from Morgan Stanley
Negative Sentiment: Coverage also notes that insiders have been trimming holdings, which may reinforce concerns that the stock’s recent gains have outpaced near-term fundamentals.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MRNA. BlackRock Inc. bought a new position in shares of Moderna in the second quarter valued at approximately $2,142,877,000. Theleme Partners LLP bought a new stake in shares of Moderna in the 2nd quarter worth $564,272,000. Capital World Investors acquired a new position in Moderna during the fourth quarter worth about $378,299,000. Wellington Management Group LLP raised its position in Moderna by 4.4% in the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after acquiring an additional 103,977 shares in the last quarter. Finally, Merck & Co. Inc. acquired a new stake in Moderna in the 2nd quarter valued at about $161,642,545. Institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on MRNA shares. Deutsche Bank Aktiengesellschaft began coverage on shares of Moderna in a report on Friday, August 28th. They set a “hold” rating on the stock. Sanford C. Bernstein restated a “market perform” rating on shares of Moderna in a research note on Friday, September 25th. Singular Research raised Moderna to a “hold” rating in a report on Wednesday, September 23rd. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a report on Wednesday, August 19th. Finally, Citigroup lowered Moderna from a “neutral” rating to a “sell” rating and boosted their price objective for the company from $60.00 to $80.00 in a research report on Wednesday, September 30th. Seven analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and an average price target of $78.17.

Read Our Latest Analysis on Moderna

Insider Transactions at Moderna

In related news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 118,882 shares of company stock valued at $16,862,280 in the last quarter. Insiders own 10.80% of the company’s stock.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Moderna

(Get Free Report)

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.